Edition:
United Kingdom

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

4.65USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,908
52-wk High
$8.04
52-wk Low
$3.63

Latest Key Developments (Source: Significant Developments)

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article

vtv Therapeutics completes enrollment of phase 2 trial evaluating TTP273 for treatment of type 2 diabetes
Tuesday, 16 Aug 2016 

vtv Therapeutics Inc : vtv therapeutics completes enrollment of phase 2 trial evaluating TTP273 for treatment of type 2 diabetes .Topline results are expected late this year.  Full Article

Vtv Therapeutics Qtrly revenue $376,000
Thursday, 12 May 2016 

Vtv Therapeutics Inc : Qtrly revenue $376,000 versus $50,000 . Qtrly loss per share $0.42 for class a common stock .Vtv therapeutics reports first quarter financial and operational results.  Full Article

vTv Therapeutics Inc initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
Thursday, 21 Jan 2016 

vTv Therapeutics Inc:Announced the enrollment of the first patients in the Company's Phase 2 LOGRA study.Topline results are expected at the end of 2016.  Full Article

BRIEF-VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes

* VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING